Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07691762 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma

Name: A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma — clinical trial record (NCT07691762)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorSuzhou Suncadia Biopharmaceuticals Co., Ltd.

Started2026-09

View on ClinicalTrials.gov ↗

Amendment history

2026-09-29

Interventions modified

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

75 trials monitored

See 7 trials at risk

Liver Cancer

1,505 trials monitored

See 60 trials at risk

This is a multicenter, Phase 3 clinical trial to evaluate the efficacy and safety of SHR-8068, Adebrelimab, and Bevacizumab and TACE versus Placebo with TACE in incurable hepatocellular carcinoma. Participants will continue treatment until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first.

Trial Details

NCT Number	NCT07691762
Lead Sponsor	Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions	Hepatocellular Carcinoma
Enrollment	690 participants
Start Date	2026-09
Primary Completion	2031-04 (estimated)
Study Completion	2031-04 (estimated)
Updated on ClinicalTrials.gov	2026-09-28